Skye Bioscience (SKYE) Q4 2025 earnings review
Monotherapy Miss Forces Costly Pivot as Cash Runway Shrinks
Skye Bioscience's Q4 results delivered a harsh reality check: the 200mg nimacimab monotherapy dose failed to achieve targeted weight loss. Management is pivoting aggressively to solve the 'exposure question' by initiating an IV expansion study at 400-600mg. While the combination data with semaglutide remains a bright spot—showing 22.3% weight loss at 52 weeks and superior off-treatment maintenance—the clinical setback is costly. Cash balances plummeted from $68.4M a year ago to $25.7M. Consequently, runway guidance was quietly pulled forward from '2027' to 'Q4 2026', and explicitly excludes Phase 2b trial costs. With an unfunded pivotal trial on the horizon, massive dilution is imminent.
🐂 Bull Case
The nimacimab plus semaglutide combination demonstrated a massive 22.3% mean weight loss at 52 weeks with no observed plateau. Furthermore, the 13-week off-treatment data showed striking durability, regaining only 17.8% of lost weight compared to 37.3% for semaglutide alone.
Despite efficacy misses in monotherapy, the safety profile is completely clean. The company reported zero drug-related central nervous system (CNS) toxicity and no added gastrointestinal burden in combination, validating the peripheral-restriction mechanism.
🐻 Bear Case
Cash stands at just $25.7M. Management stated this only funds operations through Q4 2026 and explicitly excludes the anticipated clinical costs of the Phase 2b study. The company must raise significant capital shortly following a clinical miss.
The 200mg dose failed to induce expected weight loss, contradicting management's previous confidence in their PK/PD modeling. Escalating to 400mg and 600mg IV adds immense formulation and delivery complexity for a commercial obesity drug.
⚖️ Verdict: 🔴
Bearish. While the combination and durability data are scientifically impressive, the failure of the 200mg monotherapy destroys the previous timeline. The company is now in a race against a shrinking balance sheet to prove higher doses work, requiring immediate and likely highly dilutive capital raises.
Key Themes
Monotherapy Efficacy Miss Contradicts Prior Narrative
Reversing. In previous quarters, management confidently pointed to preclinical PK/PD models indicating that a 200mg dose would yield significant weight loss. This quarter, they admitted the 200mg monotherapy 'did not achieve the targeted weight-loss effect.' The narrative has shifted from celebrating a validated dose to urgently solving an 'exposure question,' significantly raising the clinical risk profile of the entire platform.
Drastically Shortened Cash Runway
Decelerating. In Q3 2025, guidance stated cash would fund operations 'into 2027.' In Q4, this was abruptly cut to 'through the fourth quarter of 2026.' Most alarmingly, management explicitly noted this runway excludes the costs of the proposed Phase 2b clinical study. With $25.7M on hand and a $14.4M quarterly burn rate, the company is effectively unfunded for its next major clinical hurdle.
Delivery Complexity: The IV Pivot
To solve the exposure failure, Skye initiated the CBeyond Expansion Study testing 400mg and 600mg administered intravenously (IV). While necessary for dose-finding, IV administration is commercially unviable for standard obesity maintenance. The company must simultaneously prove the drug works at these levels and successfully formulate it into a high-volume subcutaneous (SC) injection via their Halozyme partnership.
Superior Off-Treatment Durability
Accelerating. The 13-week post-treatment follow-up data is a major commercial differentiator. Patients on the nimacimab plus semaglutide combination regained only 17.8% of their lost weight, compared to 37.3% for those on semaglutide alone. Furthermore, the combination cohort actually gained lean mass while maintaining fat mass loss during this off-treatment period, directly addressing the incretin 'rebound' crisis.
Additive Combination Efficacy
Stable. The interim 52-week data validated nimacimab as a powerful combination agent, achieving 22.3% weight loss alongside semaglutide with no observed plateau. The 26-week data confirmed an approximate 3% incremental benefit versus semaglutide alone. If monotherapy fails entirely, this synergistic profile provides a viable fallback commercial path.
APC Pipeline Innovation Validated
Accelerating. Skye announced proof-of-concept preclinical data for a novel antibody-peptide conjugate (APC) that unites nimacimab's CB1 inhibition with a GLP-1 receptor agonist in a single unimolecular therapeutic. Dosed every three days in models, it matched the efficacy of a daily combination regimen, paving the way for a next-generation pipeline asset.
Other KPIs
Accelerating significantly from $18.7M in 2024. The 126% YoY surge was driven by contracted manufacturing and clinical trial costs for nimacimab, reflecting the intense capital requirements of running multi-arm Phase 2a extension and expansion studies.
More than doubled from $26.6M in 2024. The massive expansion in operating loss was primarily fueled by a $20.7 million increase in contract manufacturing related to Phase 2b drug supply preparations—preparations for a trial the company currently lacks the cash to fully execute.
Guidance
Decelerating. Cut significantly from the prior 'into 2027' guidance. Crucially, this projection excludes the execution costs of the pivotal Phase 2b study, signaling an unavoidable near-term capital raise.
Stable. This pushes the next major efficacy catalyst out by nearly a year. The 16-week data for the 400mg and 600mg IV cohorts will dictate whether nimacimab has a future as a monotherapy.
Key Questions
Phase 2b Funding Strategy
You explicitly noted that current cash excludes Phase 2b trial costs. Given the current balance sheet, how much capital is required to fully fund this trial, and what are the primary avenues for securing it in a challenging biotech tape?
IV to SC Translation
The expansion study uses IV dosing for the 400mg and 600mg cohorts. Even if successful, how confident are you that the Halozyme ENHANZE technology can translate these massive exposures into a commercially viable, patient-friendly subcutaneous injection?
Monotherapy vs Combination Resource Allocation
Given the 200mg monotherapy miss and the undeniable strength of the 52-week combination data, at what point does it make strategic sense to abandon monotherapy entirely and focus all remaining capital strictly on the combination pathway?